• Murray A Raskind, Elaine R Peskind, Evan D Kanter, Eric C Petrie, Allen Radant, Charles E Thompson, Dorcas J Dobie, David Hoff, Rebekah J Rein, Kristy Straits-Tröster, Ronald G Thomas, and Miles M McFall.
• Northwest Network VISN 20 Mental Illness Research, Eduation, and Clinical Center, VA Puget Sound Healthcare System, Seattle, USA. murray.raskind@med.va.gov
• Am J Psychiatry. 2003 Feb 1; 160 (2): 371-3.

ObjectivePrazosin is a centrally active alpha(1) adrenergic antagonist. The authors' goal was to evaluate prazosin efficacy for nightmares, sleep disturbance, and overall posttraumatic stress disorder (PTSD) in combat veterans.MethodTen Vietnam combat veterans with chronic PTSD and severe trauma-related nightmares each received prazosin and placebo in a 20-week double-blind crossover protocol.ResultsPrazosin (mean dose=9.5 mg/day at bedtime, SD=0.5) was superior to placebo for the three primary outcome measures: scores on the 1) recurrent distressing dreams item and the 2) difficulty falling/staying asleep item of the Clinician-Administered PTSD Scale and 3) change in overall PTSD severity and functional status according to the Clinical Global Impression of change. Total score and symptom cluster scores for reexperiencing, avoidance/numbing, and hyperarousal on the Clinician-Administered PTSD Scale also were significantly more improved in the prazosin condition, and prazosin was well tolerated.ConclusionsThese data support the efficacy of prazosin for nightmares, sleep disturbance, and other PTSD symptoms.

29 keywords...

hide…